Khoso Baluch Net Worth

The estimated Net Worth of Khoso Baluch is at least $2.22 Milion dollars as of 13 August 2020. Mr. Baluch owns over 4,830 units of CorMedix Inc stock worth over $420,854 and over the last 8 years he sold CRMD stock worth over $0. In addition, he makes $1,795,830 as Chief Executive Officer, Interim Principal Accounting Officer oraz Director at CorMedix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Baluch CRMD stock SEC Form 4 insiders trading

Khoso has made over 9 trades of the CorMedix Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 4,830 units of CRMD stock worth $19,996 on 13 August 2020.

The largest trade he's ever made was buying 104,166 units of CorMedix Inc stock on 12 December 2017 worth over $50,000. On average, Khoso trades about 16,950 units every 84 days since 2016. As of 13 August 2020 he still owns at least 60,905 units of CorMedix Inc stock.

You can see the complete history of Mr. Baluch stock trades at the bottom of the page.

Khoso Baluch biography

Khoso Baluch serves as Chief Executive Officer, Interim Principal Accounting Officer, Director of the Company. Mr. Baluch previously served as Senior Vice President and President Europe, Middle East & Africa EMEA of UCB, SA, or UCB, from January 2015 to early 2016, Senior Vice President and President of the European Region of UCB from February 2013 to December 2014, and Senior Vice President and Chief Marketing Officer of UCB from January 2010 to February 2013. Prior to joining UCB, Mr. Baluch worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. He has served as an independent director of Poxel SA, a French publically traded biotech company, since 2013. Mr. Baluch holds a BSc in Aeronautical Engineering from City University London and a Masters of Business Administration from Cranfield School of Management.

What is the salary of Khoso Baluch?

As the Chief Executive Officer, Interim Principal Accounting Officer oraz Director of CorMedix Inc, the total compensation of Khoso Baluch at CorMedix Inc is $1,795,830. There are no executives at CorMedix Inc getting paid more.

How old is Khoso Baluch?

Khoso Baluch is 61, he's been the Chief Executive Officer, Interim Principal Accounting Officer oraz Director of CorMedix Inc since 2020. There are 9 older and 4 younger executives at CorMedix Inc. The oldest executive at CorMedix Inc is John L. Armstrong Jr., 76, who is the Exec. VP for Technical Operations.

What's Khoso Baluch's mailing address?

Khoso's mailing address filed with the SEC is C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 14 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish oraz Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Mr. Baluch stock trades at CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer